Marker Therapeutics Shares Rise on Key FDA Designation

 Shares of Marker Therapeutics Inc. rose more than 10% in premarket trading Thursday after the clinical-stage immuno-oncology company said the U.S. Food and Drug Administration granted orphan-drug designation to its MT-601 T-cell therapy for the treatment of pancreatic cancer.

The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing-exclusivity period against competition.

Houston-based Marker said MT-601 is its second multi-antigen targeted T-cell therapy to receive the designation, and its first in a solid tumor indication.

https://www.marketscreener.com/quote/stock/MARKER-THERAPEUTICS-INC-46699740/news/Marker-Therapeutics-Shares-Rise-Premarket-on-Key-FDA-Designation-37595672/